P123 Biologic dose tapering: a patient perspective

Abstract Background/Aims Biological therapies target specific pathways within the inflammatory process involved in pathogenesis of rheumatoid arthritis. They are costly and can be associated with side-effect burden for patients. Evidence on whether medications stopped or tapered stable patients remission very low disease activity is limited. This approach may benefit by limiting side-effects costs. Alongside understanding efficacy dose tapering it also necessary to gain insight into how perceive this approach. Our aim was identify key themes that arise when discuss their perspective biologic tapering. Methods 213 arthritis Cardiff & Vale Health Board sub-cutaneous anti-TNF agents (certolizumab, etanercept, adalimumab, golimumab) were identified. An inclusion/exclusion criterion then formulated after consultant review determine which remission/low suitable 80/213 qualified, a digital questionnaire sent 52/80 where 23/52 (44% response rate) responded. The included single multiple questions. Open text answers available if wanted include any other comments. focused 4 main insights: Knowledge, Experience, Perspective Practicalities. Questionnaire data thematically analysed. Results 3 became prominent: [1] Hesitancy, [2] Fear, [3] Information. 83% had never heard before questionnaire, 61% ‘unsure’ initial thoughts 30% being considered indicates limited contribute patient hesitancy. 18% initially ‘fearful’ afraid ‘flaring’ again. Patients fearful ‘length time they need wait an appointment’ flared, 57% wanting ‘access help there flare’. concept fear multi-faceted occurring both patients’ concerns surrounding practicalities related care. 35% believed did not have enough ‘information’ 45% receiving more about would make them comfortable idea. Conclusion hesitancy exposure information - demonstrating barrier. preferred mode contact virtual face-to-face support, just solely face-to-face. Rheumatologists as source tapering, discussed leaflets, case histories websites future discussions These perspectives will us develop implement strategy our department. Disclosure R. Rahman: None. C. Beynon: